Article
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.
The lancet. HIV - 1 Sept 2021
Madhi Shabir A, Koen Anthonet L, Izu Alane, Fairlie Lee, Cutland Clare L, Baillie Vicky, Padayachee Sherman D, Dheda Keertan, Barnabas Shaun L, Bhorat Qasim Ebrahim, Briner Carmen, Aley Parvinder K, Bhikha Sutika, Hermanus Tandile, Horne Elizea, Jose Aylin, Kgagudi Prudence, Lambe Teresa, Masenya Masebole, Masilela Mduduzi, Mkhize Nonhlanhla, Moultrie Andrew, Mukendi Christian K, Moyo-Gwete Thandeka, Nana Amit J, Nzimande Ayanda, Patel Faeezah, Rhead Sarah, Taoushanis Carol, Thombrayil Asha, van Eck Samuel, Voysey Merryn, Villafana Tonya L, Vekemans Johan, Gilbert Sarah C, Pollard Andrew J, Moore Penny L, Kwatra Gaurav
Abstract excerpt
BACKGROUND: People living with HIV are at an increased risk of fatal outcome when admitted to hospital for severe COVID-19 compared with HIV-negative individuals. We aimed to assess safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in people with HIV and HIV-negative individuals in South Africa. METHODS: In this ongoing, double-blind, placebo-controlled, phase 1B/2A trial (COV005), people with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.